Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Derman

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Hematology. American Society of Hematology. Education Program|December 5, 2025
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?Benjamin A Derman
Hematology/Oncology Clinics of North America|January 6, 2024
Measurable Residual Disease and Decision-Making in Multiple MyelomaBenjamin A Derman, Rafael Fonseca
Drugs|September 4, 2025
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma TherapyJennifer H Cooperrider, Benjamin A Derman
Blood Advances|September 8, 2025
Clinical applications of mass spectrometry in multiple myelomaBenjamin A Derman, Andrew J Yee
Leukemia & Lymphoma|August 29, 2025
The role of maintenance therapy and its cessation in patients with multiple myelomaAbigail P Sneider, Benjamin A Derman
Best Practice & Research. Clinical Haematology|November 30, 2019
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?Benjamin A Derman, Richard A Larson
Seminars in Thrombosis and Hemostasis|June 17, 2015
Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective AnalysisBenjamin A Derman, Hau C Kwaan
Blood Reviews|September 4, 2021
Knowing the unknowns in high risk multiple myelomaBenjamin A Derman, Satyajit Kosuri, Andrzej Jakubowiak
International Journal of Nephrology|September 27, 2018
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple MyelomaBenjamin A Derman, Jochen Reiser, Sanjib Basu, et al.
The Oncologist|June 26, 2024
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedicationKashyap Padmaraju, Kaitlin Kelly, Andrzej J Jakubowiak, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Hematology. American Society of Hematology. Education Program|December 5, 2025
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?Benjamin A Derman
Hematology/Oncology Clinics of North America|January 6, 2024
Measurable Residual Disease and Decision-Making in Multiple MyelomaBenjamin A Derman, Rafael Fonseca
Drugs|September 4, 2025
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma TherapyJennifer H Cooperrider, Benjamin A Derman
Blood Advances|September 8, 2025
Clinical applications of mass spectrometry in multiple myelomaBenjamin A Derman, Andrew J Yee
Leukemia & Lymphoma|August 29, 2025
The role of maintenance therapy and its cessation in patients with multiple myelomaAbigail P Sneider, Benjamin A Derman
Best Practice & Research. Clinical Haematology|November 30, 2019
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?Benjamin A Derman, Richard A Larson
Seminars in Thrombosis and Hemostasis|June 17, 2015
Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective AnalysisBenjamin A Derman, Hau C Kwaan
Blood Reviews|September 4, 2021
Knowing the unknowns in high risk multiple myelomaBenjamin A Derman, Satyajit Kosuri, Andrzej Jakubowiak
International Journal of Nephrology|September 27, 2018
Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple MyelomaBenjamin A Derman, Jochen Reiser, Sanjib Basu, et al.
The Oncologist|June 26, 2024
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedicationKashyap Padmaraju, Kaitlin Kelly, Andrzej J Jakubowiak, et al.
Pageof 6